Division of Cardiovascular Medicine.
Department of Internal Medicine.
Am J Cardiol. 2023 Jul 1;198:38-46. doi: 10.1016/j.amjcard.2023.04.024. Epub 2023 May 16.
Managing atrial fibrillation (AF) risk factors (RFs) improves ablation outcomes in obese patients. However, real-world data, including nonobese patients, are limited. This study examined the modifiable RFs of consecutive patients who underwent AF ablation at a tertiary care hospital from 2012 to 2019. The prespecified RFs included body mass index (BMI) ≥30 kg/m, >5% fluctuation in BMI, obstructive sleep apnea with continuous positive airway pressure noncompliance, uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, tobacco use, alcohol use higher than the standard recommendation, and a diagnosis-to-ablation time (DAT) >1.5 years. The primary outcome was a composite of arrhythmia recurrence, cardiovascular admissions, and cardiovascular death. In this study, a high prevalence of preablation modifiable RFs was observed. More than 50% of the 724 study patients had uncontrolled hyperlipidemia, a BMI ≥30 mg/m, a fluctuating BMI >5%, or a delayed DAT. During a median follow-up of 2.6 (interquartile range 1.4 to 4.6) years, 467 patients (64.5%) met the primary outcome. Independent RFs were a fluctuation in BMI >5% (hazard ratio [HR] 1.31, p = 0.008), diabetes with A ≥6.5% (HR 1.50, p = 0.014), and uncontrolled hyperlipidemia (HR 1.30, p = 0.005). A total of 264 patients (36.46%) had at least 2 of these predictive RFs, which was associated with a higher incidence of the primary outcome. Delayed DAT over 1.5 years did not alter the ablation outcome. In conclusion, substantial portions of patients who underwent AF ablation have potentially modifiable RFs that were not well controlled. Fluctuating BMI, diabetes with hemoglobin A ≥6.5%, and uncontrolled hyperlipidemia portend an increased risk of recurrent arrhythmia, cardiovascular hospitalizations, and mortality after ablation.
管理心房颤动 (AF) 风险因素 (RFs) 可以改善肥胖患者的消融治疗效果。然而,包括非肥胖患者在内的实际数据有限。本研究在一家三级护理医院对 2012 年至 2019 年期间接受 AF 消融治疗的连续患者的可改变 RFs 进行了检查。预设的 RFs 包括体重指数 (BMI) ≥30kg/m2、BMI 波动>5%、阻塞性睡眠呼吸暂停伴持续气道正压通气不耐受、未控制的高血压、未控制的糖尿病、未控制的高血脂、吸烟、饮酒量超过标准推荐值和诊断至消融时间 (DAT) >1.5 年。主要结果是心律失常复发、心血管入院和心血管死亡的复合结果。在这项研究中,观察到消融前可改变 RFs 的高患病率。超过 724 例研究患者的 50%以上存在未控制的高血脂、BMI ≥30mg/m2、BMI 波动>5%或 DAT 延迟。在中位随访 2.6 年(四分位距 1.4 至 4.6)期间,467 例患者(64.5%)达到主要结果。独立的 RFs 是 BMI 波动>5%(风险比 [HR] 1.31,p=0.008)、糖化血红蛋白 A ≥6.5%的糖尿病(HR 1.50,p=0.014)和未控制的高血脂(HR 1.30,p=0.005)。共有 264 例患者(36.46%)至少存在 2 种这些预测性 RFs,这与主要结果的发生率较高相关。DAT 延迟超过 1.5 年不会改变消融治疗效果。总之,接受 AF 消融治疗的患者中有相当一部分存在潜在的可改变 RFs,但控制不佳。BMI 波动、糖化血红蛋白 A ≥6.5%的糖尿病和未控制的高血脂预示着消融后心律失常、心血管住院和死亡的风险增加。